Androgen deprivation therapy (ADT) remains the mainstay approach to PCa management [8, 9], achieved by surgical castration or medical therapy with gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, or androgen pathway inhibitors [8]. The gene discussed is GNRH1; the disease is posterior cortical atrophy.